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Abstract: 
Background: Neuropsychiatric SLE (NPSLE) is one of the most important manifestations of 
SLE, and includes a variety of clinical manifestations, classified by the American College of 
Rheumatology in 19 different neuropsychiatric syndromes. To date, more than 116 
antibodies have been reported in SLE and at least 20 of them, including 11 brain-specific and 
9 systemic antibodies, have been controversially associated with NPSLE.  
Objectives: To systematically review the available evidence, in order to define the 
association between the above antibodies and NPSLE as a whole and with the 19 
neuropsychiatric syndromes associated with SLE, by strictly applying the American College 
Rheumatology case definitions. 
Methods: Medline-reports published between 1999 and 2013 investigating the association 
between antibodies and NPSLE were included. Whenever possible, associations between 
antibodies and both NPSLE as a whole and with the 19 syndromes were analysed.  
Results: This systematic review is based on available data from more than 8000 patients and 
controls from 42 studies analyzing antibodies and NPSLE.  Nineteen studies analysed the 
role of antiphospholipid antibodies (aPL), 11 focused on anti-ribosomal-P protein antibodies 
and 5 on anti-N-Methyl-D-Aspartate receptor antibodies.  Two studies analysed, 
respectively, antibodies to aquaporin-4 and VH4-34 encoded antibodies. 
Conclusion: Given the multitude of clinical manifestations related to NPSLE, a single 
biomarker failed to be reliably associated with all neuropsychiatric events.  
Our findings provide evidence that aPL, mainly the Lupus Anticoagulant, and anti- ribosomal 
P antibodies are significantly associated with specific manifestations of neuropsychiatric 
disease attributed to SLE, namely cerebrovascular events and psychosis, respectively.
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INTRODUCTION: 
Systemic lupus erythematosus (SLE) is a model autoimmune disease affecting multiple organ 
systems including the skin, joints, kidneys, and nervous system. 
Neuropsychiatric SLE (NPSLE) is one of the most important manifestations of SLE, and it 
includes a variety of focal or diffuse, central or peripheral, psychiatric, isolated, complex, 
simultaneous and/or sequential symptoms and signs, representing both active and inactive 
disease states. Central nervous system disease predominates and may take the form of 
either diffuse (e.g. psychosis or depression) or focal disease (e.g. stroke or transverse 
myelitis) 1-5. 
In 1999, the American College of Rheumatology (ACR) proposed a standard nomenclature 
with case definitions for 19 neuropsychiatric syndromes associated with SLE 6. The ACR case 
definitions have provided a much needed and currently widely used platform for the 
classification of neuropsychiatric events in SLE. Yet, the detection of autoantibodies in 
serum or cerebrospinal fluid has not been included as a diagnostic marker within the 
classification. To date, more than 116 antibodies have been reported in SLE7 and at least 20 
of them, including 11 brain-specific and 9 systemic antibodies, have been associated with 
NPSLE 8. 
Available studies on the significance of different autoantibodies in NPSLE have shown 
controversial results9.  Therefore, the value of testing for these antibodies as markers of 
NPSLE remains to be determined and the strength of the association of with 19 
neuropsychiatric syndromes associated with SLE is still to be established.  
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To contribute to this issue, we carried out a systematic review of the literature.  We sought 
to identify all antibodies reported as potentially related to NPSLE in order to define their 
association with both NPSLE as a whole and with the 19 neuropsychiatric syndromes 
associated with SLE, by strictly applying the ACR case definitions.  
Patients, materials, and methods 
Data Sources and Searches 
Articles were identified by a computer-assisted search of the literature. The search strategy 
was applied to Ovid MEDLINE (R) In Process & other non-indexed citations and Ovid 
MEDLINE from 1999 through 2013. The grey literature was searched by applying a similar 
strategy to Google ScholarR, PubMedR and the Proquest Dissertation & Theses databases. 
Additional references were identified from manual review of the reference lists of included 
articles.  
A schematic representation of the search strategy, key words and subject terms used in the 
search is given in Figure 1. This approach has been previously reported and validated 10, 11. 
We conducted the search utilizing the following commonly used keywords: 
‘neuropsychiatric’ and ‘lupus’ or ‘CNS’ and ‘lupus,’ combined with ‘American College of 
Rheumatology’ or ‘ACR.’ The obtained articles were combined with a search utilizing the 
‘autoantibodies’ or ‘autoantibody’ as keywords. A follow-up of the relevant bibliography in 
articles was also undertaken to identify additional relevant articles.  
Study Selection 
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Potential studies identified with the above search strategy were exported to an electronic 
reference management software program (RefWorks v.2.0). Duplicate studies were 
identified and removed using the filter functions “exact duplicates” and “close duplicates.” 
Two independent reviewers (SS, MLB) reviewed all potential studies. Eligibility was first 
determined by review of the title and abstract and then by full article review. 
Disagreements were resolved by consensus; if consensus could not be achieved, a third 
party (GS) would provide an assessment of eligibility. As the data on eligibility were 
dichotomous (eligible: yes / no), inter-rater agreement at both the title and abstract review 
and the full article review stages was determined by calculation of Cohen’s kappa coefficient 
12. 
The patient population and laboratory methods were systematically examined. 
In details, case reports, review articles, and papers not dealing with SLE patients were 
excluded and were not further reviewed. In case an abstract was considered potentially 
relevant, the article was reviewed in full-text and assessed for relevance by applying a 
checklist of inclusion and exclusion criteria. 
Included were studies investigating NP syndromes in patients with definite systemic lupus 
erythematosus (SLE) (i.e. each patient fulfilling at least 4 ACR criteria for SLE), strictly 
applying the 1999 ACR case definitions, and having a sample size of at least 20 patients 
exploring the clinical association with one or more autoantibodies potentially related to 
NPSLE.  
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Excluded were studies that did not relate to the 19 NPSLE syndromes, studies that 
presented duplicate data, or irrelevant studies that were not identified in the initial review 
of abstracts (e.g. case reports or review articles). 
Data Extraction and Quality Assessment 
For each relevant study, we identified and recorded the total number of SLE patients, the 
number of patients having NPSLE, the number of neuropsychiatric syndromes (each patient 
could have more than 1 neuropsychiatric syndrome during the course of the disease), the 
study design and characteristics of patients, including age group (adult or pediatric). We also 
recorded the cumulative prevalence of each of the 19 NPSLE syndromes in each cohort, as 
well as the prevalence of the autoantibodies tested.  When possible, we extracted the exact 
numbers of syndromes and patients resulting positive for autoantibodies testing as reported 
in the articles. When not available we calculated them from proportions provided in the 
manuscript.  
Statistical analysis 
Odds ratio with 95% CI (OR [95%CI]) for each autoantibody in NPSLE was recorded or, if not 
available, calculated for each study, whenever possible, by means of contingency tables. In 
case-control and cross-sectional studies, contingency tables were used to compare the 
proportion of each tested autoantibody in patients with and without NPSLE. In prospective 
studies, contingency tables were established as previously reported10, 11: (1) if SLE was the 
enrolment criterion, the OR [95%CI] was calculated by comparing the proportion of each 
tested autoantibody in patients who did or did not develop NPSLE during follow-up; (2) if 
NPSLE was the enrolment criterion, the OR [95%CI]  was calculated by comparing the 
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proportion of each tested autoantibody in patients with or without recurrent NPSLE during 
follow-up; and (3) if positivity for each tested autoantibody was the enrolment criterion, the 
OR [95%CI]  was calculated by comparing the rates of thrombosis during follow-up of 
patients grouped according to different antibody types and titers.  
Risk of Bias Assessment 
One reviewer (SS) assessed the risk of bias of individual studies using the Newcastle-Ottawa 
Scale (NOS) for cohort studies, and the NOS for case control studies. The NOS is a scoring 
tool used to assess quality of evidence and risk of bias for non-randomized studies included 
in meta-analyses13. The overall quality of evidence was determined using GRADE criterion 
and summarized using GRADE profiler 14.  
Results 
Literature search strategy and articles retrieved 
Forty-two articles were retrieved.  Nineteen studies 15-33 analysed the role of 
antiphospholipid antibodies (aPL), eleven16, 20, 25-27, 34-39 focused on anti-ribosomal P protein 
antibodies and 5 on anti-N-Methyl-D-Aspartate (NMDA) receptor antibodies18, 19, 25, 40, 41.  
Two studies, respectively, analysed antibodies to aquaporin-442 and VH4-34 encoded 
antibodies43. Nine studies44-52 studies were excluded because it was not possible to extract 
the exact numbers of syndromes and/or patients resulting positive for autoantibodies 
tested or because they were not relevant for the purpose of this review.. Four studies53-56 
were also excluded as they focused on other biomarkers than autoantibodies.  
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Three further publications57-59 were obtained from review of the reference lists of included 
articles.  
Overall, all studies included gave information on 8000 patients. While most of the studies 
were of a retrospective design, 4 studies, contributing with 2447 patients were prospective 
27, 31, 36, 60.  
SLE was the enrolment criteria in all the studies. 
The lack of objective documentation of temporal sequence between measurement of the 
autoantibody and the time of the events, and the absence of a control group greatly 
reduced the level of evidence. Ten studies15, 18, 20-22, 25-27, 31, 35 performed multivariate 
analysis using logistic regression.  
Antiphosholipid antibodies (aPL) 
Most aPL, in particular, anticardiolipin (aCL) and lupus anticoagulant (LAC), have been the 
most widely investigated autoantibodies in NPSLE. There is abundant research on their 
association with focal manifestations such as stroke, seizures, epilepsy, and migraine 
headaches, and diffuse neurological manifestations including cognitive impairment. We 
retrieved nineteen studies 15-33 dealing with the role of aPL in NP manifestations in SLE 
(Table 1). While some of the studies dealt directly with possible association of aPL with 
NPSLE in general, others focused on specific manifestations within the 19 neuropsychiatric 
syndromes associated with SLE.  
A strong correlation between aPL and the overall frequency of neuropsychiatric 
manifestations was reported in many studies15, 17, 22, 24, 31, but refuted in others19, 28-30.  
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In pediatric SLE, elevated titers of aCL and LAC have been reported and associated with NP 
manifestations23, 24, especially with cerebrovascular involvement23. One study29  could not 
confirm this association.  
 In adult SLE patients, aCL have been found to be associated with an overall NPSLE 
involvement more often than LA17, 20, 24, 31, 33. However, when investigating cerebrovascular 
disease (CVD), predominantly stroke16, 18, 20, 23, 25, 26, 33, the LAC has been proved to be the 
most strongly associated aPL16, 25, 26. aPL have also been found associated with seizures20, 21, 
61. 
A recent prospective study including 1047 SLE patients refuted the association between aPL 
and seizures27, but confirmed LA as a biomarker for increased risk of intracranial thrombosis 
in a previous study from the same cohort26. Of note, neuropsychiatric damage is prevalent 
in Chinese patients with SLE and seems to be independently associated with aPL22.  
One study on SLE patients without overt NPLSE, used the Wechsler Adult Intelligence Scale 
(WAIS) for  auditive  backspan showing and association between aCL and cognitive 
impairment32.  
While most studies have demonstrated an association between aCL and/or LA and NPSLE, 
the role of anti-β2 glycoprotein I (anti-β2GPI) needs further investigation, as only five16, 25, 26, 
30, 62 studies16, 25, 26, 30, 61, all failing  to show a significant association with any of the 19 
neuropsychiatric syndromes associated with SLE, are available in the literature. Overall, 
these studies show that while they can be frequently found in patients with NPSLE, aPL, 
especially LA, are strongly associated with cerebrovascular disease. 
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Anti-ribosomal P protein antibodies (anti-RP) 
Considerable data show that anti-RP antibodies are present in 6 to 46% of subjects with 
SLE63. These antibodies recognize 3 specific ribosomal proteins termed P0, P1, and P2, which 
carry molecular weights of 35, 19, and 17 kd, respectively 64-66. One of the major points of 
interest of anti-RP derives from their high specificity for SLE64-66. Elevated titers of anti-RP 
are mainly detected in SLE patients during active disease and may be associated with 
particular clinical manifestations including NPSLE8. Eleven studies were identified in which 
anti-RP antibodies and NPSLE were reported16, 20, 25-27, 34-39. One further publication58 was 
obtained from review of the reference lists of included articles. All data are summarised in 
Table 2. All the available studies refuted the association between anti-RP antibodies and 
NPSLE manifestations as a whole13, 17, 22-24, 31-35,39. 
In contrast, the association between anti-RP and psychosis, originally described by Bonfa 
and coworkers in two patients with active lupus psychosis67, was largely confirmed in 
subsequent studies. Four studies2, 22, 25, 31  including 1710 patients confirmed the association 
between elevated titers of anti-RP antibodies and psychosis. Moreover, data from the 
largest multicenter prospective study in the field conducted by members of the Systemic 
Lupus International Collaborating Clinics (SLICC) 68, provides evidence that anti-RP are 
significantly associated with psychosis attributed to SLE26.  
In contrast, an international meta-analysis combining standardized data from 1,537 lupus 
patients from 14 research centres refuted the association between anti-RP and any 
manifestation of NPSLE39. This meta-analysis aimed at evaluating the diagnostic accuracy of 
anti-RP for NPSLE as a whole as well as for psychosis, mood disorder or both, and for other 
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diffuse manifestations. The reported sensitivity and specificity estimates for the diagnosis of 
NPSLE were 26%  [95% CI 15–42%] and 80% [95% CI 74–85%], respectively. For psychosis, 
mood disorder or both, the sensitivity and specificity were 27% [95% CI 14–47%] and 80% 
[95% CI 74–85%], respectively. For other diffuse manifestations, the sensitivity was 24% 
[95% CI 12– 42%] and the specificity 80% [95% CI 73–85%].  These results were supported 
by published studies. While the sensitivity for psychosis and/or mood disorder was slightly 
improved, it was still suboptimal (42% [95% CI 30–53%]). The specificity remained similar to 
that from published data (81% [95% CI 76–85%])39.  
In summary, anti-RP testing does not discriminate between patients with NPLSE 
manifestations (diffuse or focal) from those without. In view of the contradictory reports, 
the issue of an association of these antibodies with NPSLE as a whole remains still 
contentious. Conversely, patients with psychotic manifestations are reported to have higher 
titers of anti-RP and testing for these antibodies can help to differentiate these patients 
from those with other thrombotic and/or inflammatory manifestations.  
Anti-N-Methyl-D-Aspartate (NMDA) Receptor antibodies 
The NMDA receptors NR2a and NR2b that bind the neurotransmitter glutamate are present 
on neuronal cells throughout the brain and play a role in many neurological functions 
including memory and learning8. Studies in animal models of SLE have shown that a subset 
of anti-double-stranded (ds) DNA antibodies cross-react with the extracellular, ligand-
binding domain of NR2 receptors, thereby suggesting a plausible biological role for these 
autoantibodies in the pathogenesis of NPSLE69. 
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 We found 5 studies assessing NMDA antibodies in SLE patients18, 19, 25, 40, 41, all failing to 
show an association with clinically overt NPSLE. 
Three further publications were obtained from review of the reference lists of included 
articles57-59. While one of those59 showed and association between serum anti-NR2 
antibodies and depressive mood (but not with cognitive dysfunction), Fragoso-Loyo et al. 
reported no association58.  
More recently, Gono et co-workers analysing a cohort of 107 SLE patients, found that NPSLE 
was the most significant independent variable associated with anti-NR2A antibody 
positivity, as estimated by multiple linear regression analysis57.  
Taken together, data show that anti-NR2 antibodies can occur in up to 30% of patients with 
SLE28. Nevertheless, they are infrequent in the antibodiesence of detectable anti-dsDNA 
antibodies and their presence in the circulation is not associated with any of the 19 
neuropsychiatric syndromes associated with SLE .  
 
Other Antibodies 
Other two studies, one analysing the antibodies to aquaporin-442, 57 and the other VH4-34 
encoded antibodies43 were retrieved. Zavada et al42 investigated the  seroprevalence and 
specificity of anti-aquaporin 4 antibodies (also known as AQP4-antibodies or NMO-IgG)  in 
patients with NPSLE. Out of 76 SLE patients, 50 met the ACR case definitions of NPSLE. Out 
of these 50,  anti-aquaporin 4 antibodies were positive in only one case.  This patient 
suffered from transverse myelitis, ranging over two vertebral segments on spinal MRI. None 
of the 75 NPSLE without transverse myelitis was found to be seropositive for anti-aquaporin 
4 antibodies.  
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Bath et al43 carried on a study to determine the clinical significance of elevated serum levels 
of VH4-34 encoded IgM and IgG antibodies with respect to the clinical characteristics of SLE. 
The self-specificities of VH4-34 encoded antibodies include red blood cells, B lymphocytes, 
and autoantigens such as single stranded DNA and cardiolipin. The authors reported that 
while IgG VH4-34 was positive in all patients with the most severe SLE manifestations, such 
as NPSLE, their IgM isotype was lacking, suggesting that isotype switching of VH4-34 
encoded antibodies or loss of VH4-34 IgM encoded antibodies may influence the 
progression of disease in SLE. 
 
Conclusion 
 
We have systematically reviewed the usefulness of measuring selected antibodies 
potentially associated with NPSLE.  To the best our knowledge, this is the first study to 
compile the body of data in the field strictly using the 1999 ACR case definitions.  
As expected, given the multitude of clinical manifestations related to NPSLE, it was very 
unlikely that a single biomarker could reliably be associated with all neuropsychiatric events.  
Our findings provide evidence that aPL, mainly LA, and anti-RP antibodies are significantly 
associated with specific manifestations of neuropsychiatric disease attributed to SLE, 
namely cerebro-vascular events and psychosis, respectively.  
It is also true that our study has some limitations, as this approach was influenced by 
significant between-study heterogeneity. We addressed heterogeneity by strictly applying 
ACR case definition as inclusion criteria. We acknowledge that by using this approach some 
studies only focusing on specific neuropsychiatric manifestations but not referring to the 
ACR case definition were left out of the analysis, leading to possible underestimation of 
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some associations between NPSLE manifestations and selected antibodies. Therefore, as per 
any review, caution in interpreting or generalizing the findings is mandatory.  
Finally, time frame between clinical presentation and autoantibody testing was not available 
for most of the included studies, limiting the possibility to perform any further sub-analysis.  
In conclusion, the diagnosis of NPSLE has still to be determined primarily by clinical 
assessment. The use of antibodies testing can help to confirm a suspected diagnosis in 
selected clinical settings. The use of a large panel of antibodies as screening for NPSLE is not 
supported by the currently available evidence.  
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Table 2: Anti-RP and NPSLE:  main characteristics of 12 articles on 4905 patients  
 
* not confirmed after further analysis 
Article Year Number of 
patients 
Study design Associated clinical manifestation 
Gerli et al. 2002 149 prospective no association 
Brey et al. 2002 128 longitudinal 
study 
no association 
Mikdashi et al. 2004 130 longitudinal 
study 
no association 
Yoshio et al. 2005 70 cross-sectional no association 
Karassa et al. 2006 1537 Meta-analysis no association 
Abdel-Nasser et al. 2008 32 cross-sectional mood disorder, borderline association 
with  Psychosis 
Hanly et al. 2008 412 retrospective psychosis 
Fragoso-Loyo et al. 2008 47 Longitudinal  
Study 
no association 
Briani et al. 2009 219 retrospective psychosis, mononeuropathy multiplex* 
Jarpa  et al. 2011 87 cross-sectional no association 
Hanly et al. 2011 1047 prospective psychosis 
Hanly et al. 2012 1047 prospective no association with seizures 
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LEGEND 
Figure 1: Literature search strategy on the association between NPSLE and autoantibodies. 
 
Table 1: aPL and NPSLE:  main characteristics of 19 articles on 6239 patients  
 
Table 2: Anti-RP and NPSLE:  main characteristics of 12 articles on 4905 patients 
 
